Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]

Affiliations

¹ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston; University of Queensland, Brisbane, Australia. Electronic address: brett.hughes@health.qld.gov.au.
² Hospital Vall D Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
³ University of Lille, Inserm U 1189, CHU Lille, Lille, France.
⁴ Oslo Universitetssykehus, Oslo, Norway.
⁵ Department of Dermatology and Allergy, Skin Cancer Center Hannover, Medizinische Hochschule Hannover, Hanover; Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Minden, Germany.
⁶ Jewish General Hospital, Montreal, Canada.
⁷ Centro Estatal de Cancerologiade Chihuahua, Chihuahua, Mexico.
⁸ Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
⁹ Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
¹⁰ Dermatology Department, Center Hospitalier Universitaire de Reims-Hôpital Robert Debre, Reims.
¹¹ Dermatology, Institut Universitaire du Cancer and CHU de Toulouse, Toulouse, France.
¹² Department of Medical Oncology, Townsville University Hospital, Townsville, Australia.
¹³ The Head and Neck Center, Oncology Department, Rambam Health Care Campus, Haifa, Israel.
¹⁴ Merck & Co., Inc., Kenilworth, USA.
¹⁵ Service de Dermatologie et Cancérologie Cutanée, Aix-Marseille University, Marseille, France.

Free article

Published Erratum

B G M Hughes et al. Ann Oncol. 2022 Aug.

Free article

. 2022 Aug;33(8):853.

doi: 10.1016/j.annonc.2022.05.517. Epub 2022 Jun 9.

¹ Cancer Care Services, Royal Brisbane and Women's Hospital, Herston; University of Queensland, Brisbane, Australia. Electronic address: brett.hughes@health.qld.gov.au.
² Hospital Vall D Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
³ University of Lille, Inserm U 1189, CHU Lille, Lille, France.
⁴ Oslo Universitetssykehus, Oslo, Norway.
⁵ Department of Dermatology and Allergy, Skin Cancer Center Hannover, Medizinische Hochschule Hannover, Hanover; Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Minden, Germany.
⁶ Jewish General Hospital, Montreal, Canada.
⁷ Centro Estatal de Cancerologiade Chihuahua, Chihuahua, Mexico.
⁸ Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
⁹ Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
¹⁰ Dermatology Department, Center Hospitalier Universitaire de Reims-Hôpital Robert Debre, Reims.
¹¹ Dermatology, Institut Universitaire du Cancer and CHU de Toulouse, Toulouse, France.
¹² Department of Medical Oncology, Townsville University Hospital, Townsville, Australia.
¹³ The Head and Neck Center, Oncology Department, Rambam Health Care Campus, Haifa, Israel.
¹⁴ Merck & Co., Inc., Kenilworth, USA.
¹⁵ Service de Dermatologie et Cancérologie Cutanée, Aix-Marseille University, Marseille, France.

No abstract available

Erratum for

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Hughes BGM, et al. Ann Oncol. 2021 Oct;32(10):1276-1285. doi: 10.1016/j.annonc.2021.07.008. Epub 2021 Jul 20. Ann Oncol. 2021. PMID: 34293460 Clinical Trial.